Pulse Therapeutics is proud to announce its merger with ICHOR Vascular and the subsequent creation of Euphrates Vascular. For more information, contact CEO Sean Morris.

Euphrates Vascular Featured in Endovascular Today

Euphrates Vascular was recently featured in Endovascular Today. The article, “Euphrates Vascular’s Ichor Reperfusion System Cleared by FDA,” discusses how the newly-approved Ichor system targets vascular occlusions by eliminating the need for surgery or drug therapies.


  • Euphrates Vascular received FDA 510(k) clearance for the sale of its Ichor percutaneous reperfusion system, which is designed to treat organized thrombus and embolic events in the peripheral vasculature.
  • Ichor is a one-size-fits-all system that replicates the standard of care of surgical embolectomy/thrombectomy but in a minimally invasive manner.
  • “Ichor will be an extraordinary tool in the clot management toolbox due to its ability to handle the organized clot many physicians struggle to treat,” said Troy Long, MD.

Read the full article.

Posted in